Thermo Fisher Scientific Inc. $TMO Shares Purchased by Goldstein Advisors LLC

Goldstein Advisors LLC boosted its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.7% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 632 shares of the medical research company’s stock after buying an additional 76 shares during the quarter. Goldstein Advisors LLC’s holdings in Thermo Fisher Scientific were worth $256,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Novare Capital Management LLC grew its position in Thermo Fisher Scientific by 8.1% during the 2nd quarter. Novare Capital Management LLC now owns 24,496 shares of the medical research company’s stock worth $9,932,000 after purchasing an additional 1,834 shares in the last quarter. Koshinski Asset Management Inc. grew its position in Thermo Fisher Scientific by 3.1% during the 2nd quarter. Koshinski Asset Management Inc. now owns 3,236 shares of the medical research company’s stock worth $1,312,000 after purchasing an additional 96 shares in the last quarter. Citizens Business Bank grew its position in Thermo Fisher Scientific by 0.7% during the 2nd quarter. Citizens Business Bank now owns 6,254 shares of the medical research company’s stock worth $2,536,000 after purchasing an additional 42 shares in the last quarter. Curbstone Financial Management Corp grew its position in Thermo Fisher Scientific by 3.8% during the 2nd quarter. Curbstone Financial Management Corp now owns 1,366 shares of the medical research company’s stock worth $554,000 after purchasing an additional 50 shares in the last quarter. Finally, VELA Investment Management LLC grew its position in Thermo Fisher Scientific by 138.3% during the 2nd quarter. VELA Investment Management LLC now owns 5,622 shares of the medical research company’s stock worth $2,279,000 after purchasing an additional 3,263 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the stock. Barclays lifted their price objective on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an “overweight” rating in a research report on Thursday, October 2nd. Wall Street Zen cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Sunday, October 12th. Raymond James Financial restated an “outperform” rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Robert W. Baird boosted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Finally, Wells Fargo & Company lowered their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an “overweight” rating on the stock in a report on Thursday, July 24th. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $589.10.

Thermo Fisher Scientific Stock Up 0.4%

TMO stock opened at $539.05 on Friday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a fifty day simple moving average of $495.74 and a 200 day simple moving average of $449.13. The firm has a market cap of $203.55 billion, a PE ratio of 31.18, a PEG ratio of 2.93 and a beta of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 EPS. Thermo Fisher Scientific’s quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Insider Activity at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares of the company’s stock, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marc N. Casper sold 400 shares of Thermo Fisher Scientific stock in a transaction on Friday, September 5th. The shares were sold at an average price of $500.50, for a total transaction of $200,200.00. Following the completion of the sale, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $56,937,881. The trade was a 0.35% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.